Characteristics of 204 patients with ankylosing spondylitis in western Sweden.
| Characteristics | No. Patients (%) or Median (range) |
|---|---|
| Sex | |
| Women | 87 (43) |
| Men | 117 (57) |
| Age, yrs | 49 (17, 78) |
| Current smokers | 24 (12) |
| Ever smokers (current + prior smokers during ≥ 6 mos) | 93 (46) |
| Years since symptom onset | 24 (2, 55) |
| Years since diagnosis | 12 (1, 47) |
| Present or past anterior uveitis | 102 (50) |
| Present or past peripheral arthritis | 120 (59) |
| Present or past coxitis | 17 (8) |
| BASMI, score | 3.0 (0.6, 7.4) |
| BASDAI, score | 3.5 (0, 9.6) |
| BAS-G, score | 2.9 (0, 10) |
| ASDAS-CRP, score | 2.3 (0.8, 5.9) |
| mSASSS, score | 5.5 (0, 72) |
| ESR, mm/h | 11 (2, 105) |
| CRP, mg/l | 5 (3, 80) |
| Hemoglobin, g/l | 139 (105, 166) |
| HLA-B27 positive | 178 (87) |
| Patients taking NSAID | 158 (77) |
| Patients taking DMARD | 62 (30) |
| Patients taking TNF-α blocker | 42 (21) |
| Patients taking bisphosphonate | 8 (4) |
| Patients taking glucocorticoid | 7 (3) |
ASDAS-CRP: Ankylosing Spondylitis Disease Activity Score using CRP; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BAS-G: Bath Ankylosing Spondylitis global patient score; BASMI: Bath Ankylosing Spondylitis Metrology Index; CRP: C-reactive protein; DMARD: disease-modifying antirheumatic drug; ESR: erythrocyte sedimentation rate; mSASSS: modified Stoke Ankylosing Spondylitis Spine Score; NSAID: nonsteroidal antiinflammatory drug; TNF: tumor necrosis factor.